1
|
Miranda-Muñoz K, Midkiff K, Woessner A, Afshar-Mohajer M, Zou M, Pollock E, Gonzalez-Nino D, Prinz G, Hutchinson L, Li R, Kompalage K, Culbertson CT, Tucker RJ, Coetzee H, Tsai T, Powell J, Almodovar J. A Multicomponent Microneedle Patch for the Delivery of Meloxicam for Veterinary Applications. ACS NANO 2024. [PMID: 39225687 DOI: 10.1021/acsnano.4c08072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/04/2024]
Abstract
This study evaluates the use of poly(vinyl alcohol), collagen, and chitosan blends for developing a microneedle patch for the delivery of meloxicam (MEL). Results confirm successful MEL encapsulation, structural integrity, and chemical stability even after ethylene oxide sterilization. Mechanical testing indicates the patch has the required properties for effective skin penetration and drug delivery, as demonstrated by load-displacement curves showing successful penetration of pig ear surfaces at 3N of normal load. In vitro imaging confirms the microneedle patch penetrates the pig's ear cadaver skin effectively and uniformly, with histological evaluation revealing the sustained presence and gradual degradation of microneedles within the skin. Additionally, in vitro drug diffusion experiments utilizing ballistic gel suggest that microneedles commence dissolution almost immediately upon insertion into the gel, steadily releasing the drug over 24 h. Furthermore, the microneedle patch demonstrates ideal drug release capabilities, achieving nearly 100% release of meloxicam content from a single patch within 18 h. Finally, in vivo studies using pigs demonstrate the successful dissolution and transdermal drug delivery efficacy of biodegradable microneedle patches delivering meloxicam in a porcine model, with over 70% of microneedles undergoing dissolution after 3 days. While low detectable meloxicam concentrations were observed in the bloodstream, high levels were detected in the ear tissue, confirming the release and diffusion of the drug from microneedles. This work highlights the potential of microneedle patches for controlled drug release in veterinary applications.
Collapse
Affiliation(s)
- Katherine Miranda-Muñoz
- Department of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States
| | - Kirsten Midkiff
- Department of Animal Sciences, University of Arkansas, B110 Agriculture, Food and Life Sciences Building, Fayetteville, Arkansas 72701, United States
| | - Alan Woessner
- Department of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States
- Arkansas Integrative Metabolic Research Center, University of Arkansas, Fayetteville, Arkansas 72701, United States
| | - Mahyar Afshar-Mohajer
- Department of Mechanical Engineering, University of Arkansas, 204 Mechanical Engineering Building, Fayetteville, Arkansas 72701, United States
| | - Min Zou
- Department of Mechanical Engineering, University of Arkansas, 204 Mechanical Engineering Building, Fayetteville, Arkansas 72701, United States
| | - Erik Pollock
- Department of Biological Sciences, University of Arkansas, Fayetteville, Science Engineering Building, Fayetteville, Arkansas 72701, United States
| | - David Gonzalez-Nino
- Department of Civil Engineering, University of Arkansas, 4190 Bell Engineering Center, Fayetteville, Arkansas 72701, United States
| | - Gary Prinz
- Department of Civil Engineering, University of Arkansas, 4190 Bell Engineering Center, Fayetteville, Arkansas 72701, United States
| | - Lillian Hutchinson
- Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas 72701, United States
| | - Ruohan Li
- Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas 72701, United States
| | - Kushan Kompalage
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, 213 CBC Building, 1212 Mid-Campus Dr North, Manhattan, Kansas 66506, United States
| | - Christopher T Culbertson
- Department of Chemistry, Kansas State University, 228 Coles Hall, 1710 Denison Ave, Manhattan, Kansas 66506, United States
| | - Ryan Jared Tucker
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, 213 CBC Building, 1212 Mid-Campus Dr North, Manhattan, Kansas 66506, United States
| | - Hans Coetzee
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, 213 CBC Building, 1212 Mid-Campus Dr North, Manhattan, Kansas 66506, United States
| | - Tsung Tsai
- Department of Animal Sciences, University of Arkansas, B110 Agriculture, Food and Life Sciences Building, Fayetteville, Arkansas 72701, United States
| | - Jeremy Powell
- Department of Animal Sciences, University of Arkansas, B110 Agriculture, Food and Life Sciences Building, Fayetteville, Arkansas 72701, United States
| | - Jorge Almodovar
- Department of Biomedical Engineering, College of Engineering, University of Arkansas, Fayetteville, Arkansas 72701, United States
- Ralph E. Martin Department of Chemical Engineering, University of Arkansas, 3202 Bell Engineering Center, Fayetteville, Arkansas 72701, United States
| |
Collapse
|
2
|
Ramírez-Agámez L, Hernández-Avilés C, Whitfield-Cargile CM, Coleman MC, Love CC. Treatment of mares with the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone transiently affects in vitro maturation of equine oocytes and blastocyst development after Intracytoplasmic Sperm Injection (ICSI). Theriogenology 2024; 223:53-58. [PMID: 38678696 DOI: 10.1016/j.theriogenology.2024.04.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 04/07/2024] [Accepted: 04/24/2024] [Indexed: 05/01/2024]
Abstract
Mares enrolled in assisted reproductive technologies (ARTs) programs are often treated with non-steroidal anti-inflammatory drugs (NSAIDs), particularly phenylbutazone (Bute), due to chronic lameness. The current study was performed to determine the effect of Bute administration on the developmental competence of in vitro-matured equine oocytes subjected to Intracytoplasmic Sperm Injection (ICSI). In a Preliminary Study, immature cumulus-oocyte complexes (COCs) recovered by post-mortem ovary harvested from two healthy mares (n = 2) treated for 10 days with Bute (4.4 mg/kg, PO, BID), and four non-treated healthy mares (n = 4), were matured in vitro and subjected to Piezo-driven ICSI. Lower oocyte in vitro maturation [Bute: 25% (3/12) vs. Control: 61% (28/46)] and blastocyst rates [Bute: 0% (0/12) vs. Control: 18% (5/28)] were observed in the Bute-treated when compared to the Control mares (P < 0.05). In the Main Experiment, a group of healthy mares (n = 9) received a daily dose of Bute (4.4 mg/kg, orally, SID) for 10 days. A control group of mares (n = 10) was treated with an equal volume of placebo. Mares in both groups were subjected to ultrasound-guided transvaginal oocyte aspiration (TVA) on days 3, 33, and 77 following the last dose of Bute (PT). Recovered COCs from both mare groups were matured in vitro and subjected to Piezo-driven ICSI. By day-3 PT, oocyte in vitro maturation rate was similar between mare groups [Bute: 65% (36/55) vs. Control: 67% (78/116); P > 0.05], while oocyte recovery [Bute: 53% (55/103) vs. Control: 70% (116/166)], cleavage [Bute: 31% (11/36) vs. Control: 62% (48/78)] and blastocyst rates [Bute: [0%] (0/36) vs. Control: 28% (22/78)] were significantly different (P < 0.05). By day 33 PT and 77 PT, differences on oocyte recovery, in vitro maturation, cleavage, and blastocyst rates were not observed between mare groups. In summary, the administration of Bute for 10 consecutive days (4.4 mg/kg, PO, SID, or BID) is associated with a decrease in the ability of immature equine oocytes to undergo in vitro-maturation (Preliminary Study) and develop to the blastocyst stage following ICSI (Preliminary Study and Main Experiment). This negative effect appeared to be transient, as 30- and 77-days post-treatment, no differences on in vitro maturation, cleavage or blastocyst rates were observed.
Collapse
Affiliation(s)
- Luisa Ramírez-Agámez
- Department of Large Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 77843, USA.
| | - Camilo Hernández-Avilés
- Department of Large Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 77843, USA
| | - Canaan M Whitfield-Cargile
- Department of Large Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 77843, USA; Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA
| | - Michelle C Coleman
- Department of Large Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 77843, USA; Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA
| | - Charles C Love
- Department of Large Animal Clinical Sciences, School of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, 77843, USA
| |
Collapse
|
3
|
Citarella G, Heitzmann V, Ranninger E, Bettschart-Wolfensberger R. Analgesic Efficacy of Non-Steroidal Anti-Inflammatory Drug Therapy in Horses with Abdominal Pain: A Systematic Review. Animals (Basel) 2023; 13:3447. [PMID: 38003065 PMCID: PMC10668864 DOI: 10.3390/ani13223447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Revised: 10/30/2023] [Accepted: 11/03/2023] [Indexed: 11/26/2023] Open
Abstract
This systematic review aimed to identify the evidence concerning the analgesic efficacy of non-steroidal anti-inflammatory drugs to treat abdominal pain in horses, and to establish whether one non-steroidal anti-inflammatory drug could provide better analgesia compared to others. This systematic review was conducted following the "Systematic Review Protocol for Animal Intervention Studies". Research published between 1985 and the end of May 2023 was searched, using three databases, namely, PubMed, Embase, and Scopus, using the words equine OR horse AND colic OR abdominal pain AND non-steroidal anti-inflammatory drug AND meloxicam OR flunixin meglumine OR phenylbutazone OR firocoxib OR ketoprofen. Risk of bias was assessed with the SYRCLE risk of bias tool, and level of evidence scored according to the Oxford Centre for Evidence-based Medicine. A total of 10 studies met the inclusion criteria. From those only one study judged pain with a validated pain score, and a high risk of bias was identified due to the presence of selection, performance, and "other" types of bias. Therefore, caution is required in the interpretation of results from individual studies. To date, the evidence on analgesic efficacy to determine whether one drug is more potent than another regarding the treatment of abdominal pain in horses is sparse.
Collapse
Affiliation(s)
- Gerardo Citarella
- Section of Anaesthesiology, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland; (V.H.); (E.R.); (R.B.-W.)
| | | | | | | |
Collapse
|
4
|
O’Brien M, Mochel JP, Kersh K, Wang C, Troy J. Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses. Front Vet Sci 2023; 10:1236976. [PMID: 37691633 PMCID: PMC10484477 DOI: 10.3389/fvets.2023.1236976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Accepted: 08/14/2023] [Indexed: 09/12/2023] Open
Abstract
Background Pain management is critical to equine welfare with non-steroidal anti-inflammatory drugs (NSAID) commonly used in horses. However, systemic NSAID use is limited by harmful gastrointestinal and renal side effects. Intravenous regional limb perfusion (IVRLP) is a technique used in horses that produces high, local antibiotic concentrations while limiting systemic circulation. NSAID-IVRLP would be a novel method of local pain management while limiting systemic NSAID side effects. To date, NSAID-IVRLP administration has not been reported in horses. This study aimed to identify the pharmacokinetics and local complications associated with using the NSAID phenylbutazone (PBZ) for IVRLP in six standing adult horses. Methods PBZ-IVRLP, at a dose of 2.2 mg/kg PBZ, was performed in a randomly assigned forelimb cephalic vein in 6 standing, healthy adult horses. A placebo-IVRLP was performed in the contralateral forelimb for comparison. Systemic serum and radiocarpal joint synovial fluid PBZ concentrations were identified at various timepoints (before IVRLP T-0 h, just after tourniquet removal T-0.5, 1.5, 3, 5, 12, 16, and 24 h post IVRLP) for non-compartmental pharmacokinetic analysis and concentration over time curves. Local complications associated with PBZ-IVRP were evaluated for up to 7 days following PBZ-IVRLP using physical and ultrasonographic assessment. On day 7 horses were humanely euthanized with histology performed on both forelimbs at PBZ-IVRLP and placebo-IVRLP administration sites. Results Non-compartmental pharmacokinetics for PBZ, and its major metabolite oxyphenbutazone (OBZ), were determined for serum and synovial fluid. Synovial PBZ concentrations (mean ± SD; 1.9 ± 2.1 μg/mL) were significantly lower (p = 0.03; CI,0.46-7.36) than serum PBZ concentrations (5.8 ± 5.1 μg/mL) at any time point. Physical and ultrasonographic measurements were not significantly different between PBZ- and placebo-IVRLP forelimbs. The most common histologic findings included focal deep dermal/subcutaneous hemorrhage and edema. Two horses showed perivasculitis and one horse showed a resolving thrombus in the cephalic vein of the PBZ-IVRLP limb. This horse also had severe perivasculitis and fibrinosuppurative dermatitis/panniculitis in the placebo-IVRLP limb. Conclusion PBZ-IVRLP pharmacokinetics at a 2.2 mg/kg dose showed no benefit compared to systemic PBZ administration in standing adult horses. Local complications associated with PBZ-IVRLP were similar to placebo-IVRLP on physical and ultrasonographic evaluation.
Collapse
Affiliation(s)
- Molly O’Brien
- Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States
| | - Jonathan P. Mochel
- Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University College of Veterinary Medicine, Ames, IA, United States
- College of Veterinary Medicine, University of Georgia, Athens, GA, United States
| | - Kevin Kersh
- Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States
| | - Chong Wang
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University College of Veterinary Medicine, Ames, IA, United States
- Department of Statistics, Iowa State University, Ames, IA, United States
| | - Jarrod Troy
- Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, United States
| |
Collapse
|
5
|
Costa LRR, Swiderski C, Palm C, Aleman M. Preliminary evaluation of hepatitis A virus cell receptor 1/kidney injury molecule 1 in healthy horses treated with phenylbutazone. J Vet Emerg Crit Care (San Antonio) 2023; 33:481-486. [PMID: 37436880 DOI: 10.1111/vec.13314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 05/30/2022] [Accepted: 06/02/2022] [Indexed: 07/14/2023]
Abstract
OBJECTIVES To investigate if hepatitis A virus cell receptor 1/kidney injury molecule 1 (HAVCR1/KIM1) in urine is detectable concurrently with increases in serum creatinine concentrations in horses receiving a recommended dose of phenylbutazone (PBZ) for 7 days. DESIGN Preliminary study. METHODS Ten clinically healthy horses with normal physical examination and laboratory work were randomly assigned to PBZ or placebo groups (5 each). The PBZ group received PBZ at 4.4 mg/kg mixed with corn syrup orally every 12 hours. The placebo group received corn syrup orally every 12 hours. Both groups were treated for 7 days. Kidney ultrasonography was performed, and venous blood and urine samples were collected prior to commencement and at the end of treatment. Samples from 1 additional healthy horse, 3 horses with acute kidney failure, and 1 horse with chronic kidney failure were also evaluated. RESULTS None of the 10 horses had detectable HAVCR1/KIM1 in urine at baseline. Serum creatinine concentrations in placebo group did not increase, and HAVCR1/KIM1 was undetectable in urine. At the end of treatment, 3 of 5 horses receiving PBZ developed increases in serum creatinine of >26.5 μmol/L (>0.3 mg/dL), and HAVCR1/KIM1 was detectable in urine, despite normal findings on kidney ultrasonography in all horses. CONCLUSIONS HAVCR1/KIM1 is detectable in urine and is associated with increases in serum creatinine concentrations of >26.5 μmol/L in horses following treatment with PBZ for 7 consecutive days. Thus, HAVCR1/KIM1 might aid in the early detection of acute kidney injury in horses.
Collapse
Affiliation(s)
- Lais R R Costa
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| | - Cyprianna Swiderski
- Department of Pathobiology and Population Medicine, School of Veterinary Medicine, Mississippi State University, Mississippi State, Mississippi, USA
| | - Carrie Palm
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| | - Monica Aleman
- Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
| |
Collapse
|
6
|
Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses. Animals (Basel) 2023; 13:ani13101597. [PMID: 37238029 DOI: 10.3390/ani13101597] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 04/19/2023] [Accepted: 04/21/2023] [Indexed: 05/28/2023] Open
Abstract
This review firstly examines the underlying pathophysiology of pain and inflammation associated with orthopedic disease and endotoxemia. Then, it reviews the clinical pharmacology (pharmacokinetics and pharmacodynamics) of both conventional and non-conventional NSAIDs in the adult horse, and finally provides an overview of different modalities to evaluate the therapeutic efficacy of NSAIDs in research.
Collapse
Affiliation(s)
- Melissa A Mercer
- Department of Biological Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA
| | - Jennifer L Davis
- Department of Biological Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA
| | - Harold C McKenzie
- Department of Large Animal Clinical Sciences, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA 24061, USA
| |
Collapse
|
7
|
Sarvi JY, Gardhouse SM, Kleinhenz MD, Hocker SE, Weeder MM, Montgomery SR, Rooney TA. Measurement of Cyclooxygenase Products in Plasma as Markers for Inhibition of Cyclooxygenase Isoforms by Oral Meloxicam in New Zealand White Rabbits ( Oryctolagus cuniculus ). JOURNAL OF THE AMERICAN ASSOCIATION FOR LABORATORY ANIMAL SCIENCE : JAALAS 2023; 62:254-259. [PMID: 37045554 PMCID: PMC10230532 DOI: 10.30802/aalas-jaalas-22-000109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 12/27/2022] [Accepted: 02/03/2023] [Indexed: 04/14/2023]
Abstract
Pain management in rabbits is a challenging task that is complicated by the rabbit's ability to hide signs of distress and the limited pharmacologic data available for this species. Pharmacokinetic data has shown that in rabbits, meloxicam, a nonsteroidal anti-inflammatory NSAID, reaches plasma concentrations that are known to provide analgesia in dogs and cats; these concentrations could theoretically alleviate pain in rabbits. However, the inhibitory effects of meloxicam on cyclooxygenase (COX) isoforms have not been studied in rabbits. In this study, we measured the products of COX-1 and COX-2 after the oral administration of a single 1 mg/kg dose of meloxicam to New Zealand White rabbits (n = 6). Blood samples were collected before drug administration (T0) and then at predetermined time points over 48 h. Plasma prostaglandin E₂ (PGE₂ ) and thromboxane (TxB₂) concentrations were measured as surrogate markers for COX-1 and COX-2, respectively, by using commercial ELISA kits. After meloxicam administration, both TxB₂ and PGE₂ plasma concentrations fell significantly below baseline, with maximal mean reductions to 80% and 60% of baseline at 8 h, respectively. The reduction in PGE₂ concentrations was followed by a significant increase that moved its mean plasma concentrations toward baseline between 8 and 24 h. Adverse effects such as lethargy, inappetence, or changes in fecal production were not observed in any rabbits. In conclusion, meloxicam appeared to significantly inhibit both COX-1 and COX-2 with a time course similar to previously reported meloxicam plasma concentration-time profiles in rabbits. Our data suggest that a dosage of 1 mg/kg given orally could provide analgesia to rabbits, but a more frequent dosing interval than the currently recommended daily dosing may be required to maintain clinical efficacy.
Collapse
Affiliation(s)
- Jasmine Y Sarvi
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
| | - Sara M Gardhouse
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
- Current affiliation: Evolution Veterinary Specialists, Lakewood, Colorado
| | - Michael D Kleinhenz
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
| | - Samuel E Hocker
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
- Current affiliation: Evolution Veterinary Specialists, Lakewood, Colorado
| | - Mikaela M Weeder
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
| | - Shawnee R Montgomery
- Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas
| | - Tess A Rooney
- Department of Clinical Sciences, Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, and
- Current affiliation: Department of Medicine and Epidemiology, University of California, Davis, School of Veterinary Medicine, Davis, California
| |
Collapse
|
8
|
Urayama S, Tanaka A, Kusano K, Sato H, Muranaka M, Mita H, Nagashima T, Matsuda H. Oral Administration of Meloxicam and Flunixin Meglumine Have Similar Analgesic Effects After Lipopolysaccharide-Induced Inflammatory Response in Thoroughbred Horses. J Equine Vet Sci 2023; 121:104205. [PMID: 36586521 DOI: 10.1016/j.jevs.2022.104205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/25/2022] [Accepted: 12/26/2022] [Indexed: 12/30/2022]
Abstract
Flunixin meglumine (FM), a nonselective cyclooxygenase (COX) inhibitor, is most frequently selected for the treatment of equine systemic inflammatory response syndrome (SIRS)/endotoxemia. However, FM has considerable adverse effects on gastrointestinal function. The aims of this study were to compare the effect of meloxicam (MX), a COX-2 selective inhibitor commonly used in equine clinical practice, with FM, and to investigate the potential for clinical application in horses with SIRS/endotoxemia. Fifteen horses were divided into three groups of five and orally administered MX (0.6 mg/kg), FM (1.1 mg/kg), or saline as placebo at 30 minutes after LPS challenge. Clinical parameters, including behavioral pain scores, were recorded and blood for clinical pathological data was collected at various times from 60 minutes before to 420 minutes after LPS infusion. The pain score were significantly lower in both the MX and FM groups than in the placebo group, with no significant difference between them. Body temperature was significantly lower in the MX and FM groups than in the placebo group. Heart rates and respiratory rates, hoof wall surface temperature, and leukocyte counts changed similarly between the MX and FM groups. TNF-α and cortisol were lower in the FM group than in the MX group. The results suggest that MX suppresses the inflammatory response after LPS infusion and has an analgesic effect similar to that of FM. Given the adverse effects of nonselective COX inhibitors, clinical application of MX may be beneficial in horses with SIRS/endotoxemia.
Collapse
Affiliation(s)
- Shuntaro Urayama
- Racehorse Hospital, Ritto Training Center, Japan Racing Association (JRA), Ritto-Shi, Shiga, Japan.
| | - Akane Tanaka
- Laboratory of Comparative Animal Medicine, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-Shi, Tokyo, Japan
| | - Kanichi Kusano
- Racehorse Hospital, Ritto Training Center, Japan Racing Association (JRA), Ritto-Shi, Shiga, Japan
| | - Hiroaki Sato
- Stewards Section, Ritto Training Center, JRA, Ritto-Shi, Shiga, Japan
| | - Masanori Muranaka
- Racehorse Hospital, Ritto Training Center, Japan Racing Association (JRA), Ritto-Shi, Shiga, Japan
| | - Hiroshi Mita
- Clinical Veterinary Medicine Division, Equine Research Institute, JRA, Simotsuke-Shi, Tochigi, Japan
| | - Tsuyoshi Nagashima
- Racehorse Hospital, Ritto Training Center, Japan Racing Association (JRA), Ritto-Shi, Shiga, Japan
| | - Hiroshi Matsuda
- Laboratory of Comparative Animal Medicine, Division of Animal Life Science, Institute of Agriculture, Tokyo University of Agriculture and Technology, Fuchu-Shi, Tokyo, Japan
| |
Collapse
|
9
|
Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet Anim Sci 2023; 19:100286. [PMID: 36684818 PMCID: PMC9852958 DOI: 10.1016/j.vas.2023.100286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
According to in vitro and in vivo investigations, firocoxib (FX), a second-generation coxib, is a highly selective COX-2 inhibitor in horses. With a COX-1/COX-2 IC50 ratio of 643 in horses, FX spares the COX-1 inhibitory effects. It is approved for the treatment of musculoskeletal problems and lameness in horses and dogs with osteoarthritis (OA). For the treatment of OA in horses, both an injectable formulation for IV administration at a dose of 0.09 mg/kg for five days and an oral paste formulation at a dose of 0.1 mg/kg for 14 days are licensed. Numerous analytical methods were reported in the literature to quantify FX in biological fluids, using HPLC and LC-MS. FX presents remarkable pharmacokinetics and pharmacodynamics compared to other coxibs. It has an oral bioavailability of 80% or higher and is effectively absorbed by horses. Its volume of distribution is around 2 L/kg, and it is slowly eliminated. Due to the long elimination half-life (around 2 days), which allows a once daily dosing, a single 0.3 mg/kg loading dose has been recommended. This enables the establishment of steady-state drug concentrations within 24 h, making it appropriate for acute treatment as well. Its IC80 is equal to 103 ng/mL in whole blood and, with an EC50 of 27 ng/mL, it has the highest affinity for its receptor compared to the other commonly administered NSAIDs in horses.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy,Department of Veterinary Sciences, University of Pisa, Pisa, Italy,Corresponding author.
| |
Collapse
|
10
|
Sulaiman Hameed G, Basim Mohsin Mohamed M, Naji Sahib M. Binary or ternary mixture of solid dispersion: Meloxicam case. PHARMACIA 2022. [DOI: 10.3897/pharmacia.69.e86744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The present work was carried out to assess the value of adding water insoluble polymer to meloxicam amorphous solid formulation (ASD). Meloxicam was mixed with polyvinylpyrrolidone (PVP) (1:1 ratio) as a binary mixture and with PVP and ethyl cellulose (1:1:1 ratio) as a ternary mixture. Solvent evaporation method was used to prepare ASD formulations. The differential scanning calorimetry, powder X-Ray diffraction, Cambridge Structural Database and in-vitro dissolution were performed to assess the formulas. The results showed that the addition of insoluble polymer could prevent the recrystallization process during ASD formation. However, the binary mixture showed higher drug release percentage than the ternary mixture. Therefore, a rational amount of insoluble polymer could be considered to control recrystallization and manipulate drug release from ASD formulations.
Collapse
|
11
|
Lemonnier LC, Thorin C, Meurice A, Dubus A, Touzot-Jourde G, Couroucé A, Leroux AA. Comparison of Flunixin Meglumine, Meloxicam and Ketoprofen on Mild Visceral Post-Operative Pain in Horses. Animals (Basel) 2022; 12:ani12040526. [PMID: 35203234 PMCID: PMC8868280 DOI: 10.3390/ani12040526] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/15/2022] [Accepted: 02/19/2022] [Indexed: 02/06/2023] Open
Abstract
Simple Summary Pain management following surgical intervention is key. In horses, several anti-inflammatories (flunixin meglumine, meloxicam and ketoprofen) are available for the management of pain following castration. However, their analgesic efficacy remains unclear for mild visceral pain. The aim of this study was to compare the analgesic efficacy of the above-mentioned anti-inflammatory drugs, following a simple surgery (inguinal castration). Horses were administered a randomly assigned anti-inflammatory drug before and after surgery. A pain score was recorded using a previously described pain assessment scale (PASPAS) before administration, and after the first and second administrations by a senior clinician and a veterinary student. Thirty horses were evaluated, and there was no significant effect of the drug administered on the pain score. Horse welfare was not compromised regardless of drug assigned. Horses showed mild pain post-operatively, which decreased significantly within 24 h. Pain scores were significantly different when assessed by a veterinary student and a senior clinician. The authors found that the anti-inflammatory drug studied provided a similar level of analgesia for the management of mild visceral pain in horses, but that the pain scale used is not suitable for junior evaluators or, by extension, owners. Abstract The analgesic efficacy of meloxicam and ketoprofen against equine visceral pain is unclear. The aim of this study was to compare the analgesic efficacy of meloxicam (M) and ketoprofen (K) to flunixin meglumine (F) following inguinal castration. Horses undergoing inguinal castration under general anesthesia were randomly assigned F (1.1 mg/kg), M (0.6 mg/kg) or K (2.2 mg/kg) intravenously two hours pre-operatively and 24 h later. A pain score (out of 31) was recorded blindly by a senior clinician and veterinary student before NSAIDs administration (T0), and after the first (T1) and second (T2) administrations, using a modified post-abdominal surgery pain assessment scale (PASPAS). Pain was classified as mild (score ≤ 7), moderate (score = 8–14) or severe (score > 14). Thirty horses (12 F, 10 M, 8 K) aged 6.2 ± 4.9 years, mostly warmbloods, were included. Horse welfare was not compromised regardless of the drug assigned. There was no statistically significant effect of NSAIDs on pain score. Mean pain scores were significantly higher at T1 than T0 for each NSAID (F: 5.08 ± 2.50 vs. 1.58 ± 1.38 (p < 0.001); M: 4.60 ± 2.32 vs. 1.10 ± 1.20 (p < 0.001); K: 5.25 ± 1.39 vs. 1.50 ± 1.51 (p < 0.0001)) and lower at T2 than T1 for F (2.92 ± 2.423 vs. 5.08 ± 2.50 (p < 0.001)) and M (2.90 ± 1.37 vs. 4.60 ± 2.32 (p < 0.0325)). At T1, senior pain scores were significantly different than for junior (5.56 ± 0.54 vs. 3.22 ± 0.62, p = 0.005). This study indicates that meloxicam and ketoprofen provide a similar level of analgesia to flunixin meglumine for the management of mild visceral pain in horses. PASPAS is not reliable for junior evaluators.
Collapse
Affiliation(s)
- Louise C. Lemonnier
- Department of Clinical Sciences, Equine Veterinary Teaching Hospital (CISCO), Oniris, Route de Gachet, F-44000 Nantes, France; (A.M.); (G.T.-J.); (A.C.); (A.A.L.)
- Correspondence: ; Tel.: +33-(0)2-40-68-76-64
| | - Chantal Thorin
- Nutrition PhysioPathologie et Pharmacologie, University of Nantes, Oniris, F-44000 Nantes, France;
| | - Antoine Meurice
- Department of Clinical Sciences, Equine Veterinary Teaching Hospital (CISCO), Oniris, Route de Gachet, F-44000 Nantes, France; (A.M.); (G.T.-J.); (A.C.); (A.A.L.)
| | - Alice Dubus
- Clinique Vétérinaire de Bel Air, Allée Marcel Doret, F-41000 Blois, France;
| | - Gwenola Touzot-Jourde
- Department of Clinical Sciences, Equine Veterinary Teaching Hospital (CISCO), Oniris, Route de Gachet, F-44000 Nantes, France; (A.M.); (G.T.-J.); (A.C.); (A.A.L.)
- UMR Inserm U1229–Regenerative Medecine and Skeleton, Department of Veterinary Clinical Sciences, University of Nantes, Oniris, F-44000 Nantes, France
| | - Anne Couroucé
- Department of Clinical Sciences, Equine Veterinary Teaching Hospital (CISCO), Oniris, Route de Gachet, F-44000 Nantes, France; (A.M.); (G.T.-J.); (A.C.); (A.A.L.)
- Biotargen, Normandie University, Unicaen, F-14000 Caen, France
| | - Aurélia A. Leroux
- Department of Clinical Sciences, Equine Veterinary Teaching Hospital (CISCO), Oniris, Route de Gachet, F-44000 Nantes, France; (A.M.); (G.T.-J.); (A.C.); (A.A.L.)
- l’Institut du Thorax, Université de Nantes, CHU Nantes, CNRS, INSERM, F-44000 Nantes, France
| |
Collapse
|
12
|
Fetal Congenital Diaphragmatic Hernia and Hydramnios in a Quarter Horse Mare. Vet Sci 2021; 8:vetsci8100201. [PMID: 34679031 PMCID: PMC8538503 DOI: 10.3390/vetsci8100201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2021] [Revised: 09/03/2021] [Accepted: 09/20/2021] [Indexed: 11/17/2022] Open
Abstract
Hydramnios is an excessive accumulation of fluid within the amniotic compartment. It is a rare condition in mares, often associated with fetal anomalies. Hydrops of fetal membranes predisposes to the rupture of the prepubic tendon, and many authors suggest the induction of parturition to preserve mare’s reproductive career. This report presents the case of a 15-year-old multiparous Quarter Horse mare, referred at 268 days of gestation for suspected hydrops. Repeated ultrasonographic exams confirmed an increase in the depth of the amniotic fluid and reduced fetal viability. During the hospitalization, the mare developed a partial rupture of the prepubic tendon. In this case, a conservative approach was elected, and the mare was treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and an abdominal support bandage. At 327 days of gestation, the mare gave birth to a foal with APGAR score 1. The resuscitation attempt was unsuccessful, and the foal died immediately. A post-mortem examination diagnosed a congenital diaphragmatic hernia (CDH) with pleuroperitoneal diaphragmatic eventration.
Collapse
|
13
|
Gobbi FP, Di Filippo PA, Mello LDM, Lemos GB, Martins CB, Albernaz AP, Quirino CR. Effects of Flunixin Meglumine, Firocoxib, and Meloxicam in Equines After Castration. J Equine Vet Sci 2020; 94:103229. [PMID: 33077071 DOI: 10.1016/j.jevs.2020.103229] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 08/05/2020] [Accepted: 08/05/2020] [Indexed: 10/23/2022]
Abstract
This study is "aimed" to evaluate and compare the efficacy of flunixin meglumine (FM), firocoxib (FX), and meloxicam (MX) after castration of horses. Thirty horses were submitted to open castration and divided into three groups (n = 10) depending on the anti-inflammatory drug administered: group I (GI) (FM, 1.1 mg kg1, IV, once a day [SID], 5 days); group II (GII) (FX, 0.1 mg kg1, IV, SID, 5 days), and group III (GIII) (MX, 0.6 mg kg1, IV, SID, 5 days). Clinical, behavioral, and hematological parameters and the peritoneal fluid (PF) were evaluated before (day [D] 0) and 1, 2, 3, 5, and 7 days afterward. In the postoperative, scores of limb rigidity and prepuce edema of animals of GII and GIII were greater than those of GI. Tachycardia was observed in the horses of GII and GIII and hyperthermia in GIII. An increase in the number of leukocytes, neutrophils, and monocytes without exceeding the reference values and hyperfibrinogenemia was observed in the animals of GI (D7), GII (D1-D7), and GIII (D7). There was reduction in serum protein after castration, together with an increase of this in the PF of the animals of the three groups. The PF on D0 was straw yellow and limpid, became reddish and cloudy on D1, and then gradually moved toward its normal color on the ensuing days, but without returning to normal on D7 in any of the groups. The results showed that castration triggers significant clinical and laboratory changes and that FM, FX, and MX are equally effective in controlling pain and inflammation in horses after castration; however, FM was more advantageous.
Collapse
Affiliation(s)
| | | | | | - Gabriela Bravim Lemos
- Universidade Estadual do Norte Fluminense Darcy Ribeiro, UENF, Rio de Janeiro, Brazil
| | - Carla Braga Martins
- Universidade Federal do Espírito Santo, UFES, Alegre, Espírito Santo, Brazil
| | | | - Celia Raquel Quirino
- Universidade Estadual do Norte Fluminense Darcy Ribeiro, UENF, Rio de Janeiro, Brazil
| |
Collapse
|